Patents by Inventor C. Cheng

C. Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240190892
    Abstract: The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: March 16, 2022
    Publication date: June 13, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Natalija Cernaka, Anthony K. Ogawa, Alan C. Cheng, Jianming Bao, Phillip Patrick Sharp, Jovan Alexander Lopez, Dong Xiao, Haiqun Tang
  • Patent number: 11931151
    Abstract: Disclosed herein is an automated urinary output measuring system. The automated urinary output measuring system includes an automated urinary output measuring device configured to be suspended from a rim of a sanitary hardware device and receive a volume of voided urine. The automated urinary output measuring device can include a receiving trough having an opening, a door configured to cover the opening in a fluid tight seal, the door coupled to the receiving trough by a hinge, and a lip extending from the receiving trough configured to detachably couple the automated urinary output measuring device to the sanitary hardware device. The system can further include an ultrasonic measuring system having a console coupled to one or more ultrasonic sensors, and a flushing mechanism coupled to the sanitary hardware device.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: March 19, 2024
    Assignee: C. R. Bard, Inc.
    Inventors: Jason Jishen Cheng, Trevor Dimicco, Audrey Earnshaw, Juan C. Tapia
  • Publication number: 20240043491
    Abstract: Provided herein are IL-2 muteins that bind to IL-2 receptor subunit but do not have measurable binding to IL-2 receptor subunit. Also provided are compositions, kits, methods, and uses involving such IL-2 muteins.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 8, 2024
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Stephen E. ALVES, Glareh AZADI, Maribel BEAUMONT, Lia BENSO, Alan C. CHENG, Peter GEORGIEV, Brian E. HALL, Veronica M. JUAN, Renee MOORE, Venkataraman SRIRAMAN, Jie ZHANG-HOOVER
  • Publication number: 20240025917
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
  • Publication number: 20230416227
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: September 9, 2021
    Publication date: December 28, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Maoqun Tian, Salman Jabri, Galen Paul Shearn-Nance, Rongze Kuang, Zhiqiang Zhao, Zhicai Wu
  • Publication number: 20230352118
    Abstract: A computer-implemented method is disclosed for candidate antibody exploration. The method includes receiving sequence reads from a sequencing system, wherein each sequence read comprises a target gene for expressing a candidate antibody, wherein each sequence read is associated with a binding affinity to a target antigen. The method includes generating a sequence representation for each sequence read, representing the amino acid sequences of the sequence read. The method includes training a binding affinity prediction model with the sequence representations and the binding affinities. The method includes generating a synthetic candidate sequence read that is different from the sequence reads. The method includes generating a sequence representation for the synthetic candidate sequence read.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 2, 2023
    Inventors: Yara Seif, Xiao Xiao, Kevin Teng, Ming-Tang Chen, Alan C. Cheng, BoRam Lee, Isha Verma
  • Publication number: 20230348428
    Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: July 6, 2021
    Publication date: November 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jacqueline D. HICKS, Rongze Kuang, Christopher J. Sinz, Matthew J. Lombardo, Jovan Alexander Lopez, Rohan Rajiv Merchant, Phillip Patrick Sharp, Zhicai Wu, Zhiqiang Zhao, Alan C. Cheng, Song Yang, Jianming Bao, Maoqun Tian, Galen Paul Shearn-Nance
  • Patent number: 11793858
    Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: October 24, 2023
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: C. Cheng Kao, Antonio Cembellin Prieto, Dean Rowe-Magnus
  • Publication number: 20230286958
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: June 10, 2021
    Publication date: September 14, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
  • Publication number: 20230272056
    Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 31, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Chung-Ming Hsieh, Michelle Castor, Ming-Tang Chen, Alan C. Cheng, Scott A. Hollingsworth, Veronica M. Juan, Madhura Shidhore, Song Yang, Renee C.T. Moore
  • Publication number: 20230265175
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: August 24, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • Patent number: 11702467
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: July 18, 2023
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • Publication number: 20230167168
    Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.
    Type: Application
    Filed: June 23, 2021
    Publication date: June 1, 2023
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
  • Publication number: 20230141928
    Abstract: Machine-learning (ML) techniques and models are described for predicting the number and severity of network attacks within a specified timeframe, such as the next fifteen minutes. In some embodiments, the techniques including training a ML model based on features extracted from a training dataset and applying the trained ML model to estimate (a) the probability of an attack happening on an account within a specified timeframe; (b) how many attacks are predicted to occur in the specified timeframe (if any); and/or (c) the severity of the attacks predicted to occur. A system may deploy preventative measures based on the ML model output to counter or mitigate the effects of predicted and coordinated network attacks.
    Type: Application
    Filed: October 13, 2021
    Publication date: May 11, 2023
    Applicant: Oracle International Corporation
    Inventors: Ján Sterba, Venkatakrishnan Gopalakrishnan, May Bich Nhi Lam, Yunjiao Xue, Nana Lei, Edward C. Cheng, Hayward Ivan Craig Welcher, Jacob Becker West, Qi Wen Cao
  • Publication number: 20230134546
    Abstract: Machine-learning techniques and models are described for alerting users to attacks on accounts in real-time or near real-time. In some embodiments, an attack detection model uses Natural Language Processing (NLP) and multi-level classification techniques to monitor login attempts and detect attacks. The model may use NLP to convert text associated with account activity to numerical vectors, where the vectors include scores and/or other numerical values computed based on the meaning of the converted text. The model may further include a set of classifiers trained to learn patterns in the numerical vectors that are predictive of a network attack. The model may assign labels to events based on the predicted likelihood that the event is an attack. The system may deploy real-time preventative or corrective measures based on the ML model output to counter or mitigate the effects of an attack.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 4, 2023
    Applicant: Oracle International Corporation
    Inventors: Venkatakrishnan Gopalakrishnan, Ján Sterba, May Bich Nhi Lam, Yunjiao Xue, Nana Lei, Edward C. Cheng, Hayward Ivan Craig Welcher, Jacob Becker West, Qi Wen Cao
  • Publication number: 20230052348
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 16, 2023
    Applicant: AMGEN INC.
    Inventors: Sean P BROWN, David Karl BEDKE, Michael R. DEGRAFFENREID, Jiasheng FU, Zhinghong LI, Felix GONZALEZ LOPEZ DE TURISO, Ana GONZALEZ BUENROSTRO, Michael W. GRIBBLE JR., Michael G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcai WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Mario G. CARDOZO, Alan C. CHENG
  • Publication number: 20230037593
    Abstract: A poroelastic biomaterial including a polyaryletherketone (PAEK) matrix polymer and a plurality of tortuous channels extending from one surface to another surface of the biomaterial is disclosed. Advantageously, the poroelastic biomaterial can have a porosity from about 5% to about 40% and high mechanical properties. The poroelastic biomaterials can be fabricated into orthopedic implant devices and can be used as a tissue scaffolds.
    Type: Application
    Filed: July 26, 2022
    Publication date: February 9, 2023
    Inventors: Tim HSU, Minren LIN, Saadyah AVERICK, Boyle C. CHENG
  • Patent number: 11429574
    Abstract: Disclosed embodiments provide a computer-implemented technique for creating a log chain from multiple software component logs. The log chain can include log information from multiple software components that interact with each other. In embodiments, a locality-sensitive hashing technique is used to create a signature of a log chain. Machine-learning systems are trained with log chains generated from test execution, and/or log chains from incidents with deployed software. In embodiments, logs are pre-processed by tokenizing and trimming. Logs from various components that interact with each other may be combined into a temporally sequential log chain. The signature of the log chain may be used to identify additional information about the error from a machine-learning process that was trained on previously generated log chains. In this way, the time required to identify a problem can be significantly reduced, resulting in increased reliability and availability of complex computer systems.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: August 30, 2022
    Assignee: International Business Machines Corporation
    Inventors: Quan Q C Cheng, Xiang Qiu, Zhi Wei Du, Peng Hui Jiang
  • Patent number: 11306107
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 19, 2022
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, David Karl Bedke, Michael R. Degraffenreid, Jiasheng Fu, Zhihong Li, Felix Gonzalez Lopez De Turiso, Ana Gonzalez Buenrostro, Michael W. Gribble, Jr., Michael G. Johnson, Todd J. Kohn, Kexue Li, Yunxiao Li, Mike Elias Lizarzaburu, Yosup Rew, Joshua Taygerly, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu, Manuel Zancanella, Xian Yun Jiao, Liusheng Zhu, Xianghong Wang, Julio C. Medina, Jason A. Duquette, Jonathan B. Houze, Marc Vimolratana, Mario G. Cardozo, Alan C. Cheng
  • Patent number: D1025075
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: April 30, 2024
    Assignee: Apple Inc.
    Inventors: Jody Akana, Molly Anderson, Bartley K. Andre, Shota Aoyagi, Anthony Michael Ashcroft, Marine C. Bataille, Jeremy Bataillou, Eric Wesley Bates, Mu-Hua Cheng, Sawyer Isaac Cohen, Markus Diebel, Richard Hung Minh Dinh, M. Evans Hankey, Julian Hoenig, Richard P. Howarth, Jonathan P. Ive, Julian Jaede, Hugh J. Jay, Duncan Robert Kerr, Peter Russell-Clarke, Benjamin Andrew Shaffer, Mikael Silvanto, Sung-Ho Tan, Clement Tissandier, Eugene Antony Whang, Rico Zörkendörfer